Skip to main content
BBOTBridgeBio Oncology Therapeutics—

BridgeBio Oncology Therapeutics (BBOT) Q2 2026 earnings — TrendMatrix coverage

IN LINEEPS — vs -$0.54 est

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q2 2026

Key numbers

Adjusted EPS
—
Estimate
-$0.54
Surprise
—

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Around the report

Coverage in the report window

  • BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate — benzinga, 2026-08-11

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › BBOT › Earnings › Q2 2026 earnings